Cannabinoid Receptor 2 (CNR2/CB2) Drug Discovery Landscape & Assay Solutions
- By admin
- 07 Oct 2026
- Comments
Market Intelligence, Clinical Progress, and High-Performance Reagents for Inflammatory, Fibrotic, and Pain Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CNR2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | CNR2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. High-titer, sequence verified. Ideal for GPCR cell-based assays. |
View CNR2 Products |
| Antigen/Lysate | CNR2 Overexpression Cell Lysate Membrane fraction preparation from HEK293. Preserves native 7-TM conformation. |
View CNR2 Products |
| Benchmark Ab | Anti-CNR2 Recombinant Antibody Sequence-derived positive control for flow cytometry and IHC validation. |
View CNR2 Products |
| Validator | CNR2 siRNA Set For knockdown verification and target specificity validation. |
View CNR2 Products |
| Related Target A | CNR1 (CB1) Essential counter-screening target to eliminate blood-brain barrier-mediated psychoactive off-target effects. |
View CNR1 Products |
| Related Target B | GPR55 Atypical cannabinoid receptor. Crucial for assessing cross-reactivity in inflammatory and pain pathways. |
View GPR55 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving Native 7-TM GPCR Conformation | Lentivirus-driven stable cell line generation (HEK293/CHO) for native functional cell-based assays (cAMP, Calcium Flux). |
| CB1/CB2 Subfamily Selectivity Screening | CNR1 (CB1) and GPR55 target reagents strictly verified by sequence and expression host for robust counter-screening. |
| Lack of Controls | Recombinant positive control antibodies and sequence-verified siRNA sets included in the assay validation package. |
| Batch-to-Batch Inconsistency | Manufactured under strict quality control. Endotoxin controlled, high purity, and theoretical MW verified. |
Live CNR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Cannabinoid Receptor 2 (CNR2/CB2) represents a highly promising frontier in immunology, pain management, and fibrotic disorders. Unlike its counterpart CNR1 (CB1), which is predominantly expressed in the central nervous system and associated with psychotropic side effects, CNR2 is primarily localized in peripheral immune cells. The race for CNR2 therapeutics is intensifying, with major players shifting focus from traditional small molecules to highly selective peripherally-restricted agonists and biologics. As first-generation therapies reach the clinic, the next wave of R&D is targeting tissue-specific delivery and biased signaling pathways to maximize anti-inflammatory efficacy while avoiding off-target liabilities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule | Corbus Pharmaceuticals, Arena Pharmaceuticals (Pfizer) | Systemic Sclerosis, Dermatomyositis, Inflammatory Bowel Disease (IBD) | Selectivity Assay (Need CNR1 vs CNR2 stable cell lines to evaluate off-target CNS binding) |
| Monoclonal Antibody | Academic Institutes, Biotech Startups | Neuropathic Pain, Autoimmune Diseases | Conformational Epitope Validation (Need high-expression CNR2 Lentivirus for flow cytometry) |
| Biased Agonists | Specialized GPCR Biotechs | Organ Fibrosis (Liver/Kidney) | Functional Signaling Assays (Need sequence-verified ORF expression vectors for cAMP/arrestin assays) |